Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
29.50
+0.80 (2.79%)
Dec 5, 2025, 4:00 PM EST - Market closed

Rapport Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
28.3822.128.181.37
Research & Development
81.7360.94284.49
Operating Expenses
110.1183.0636.185.85
Operating Income
-110.11-83.06-36.18-5.85
Interest Expense
----0.31
Interest & Investment Income
12.4112.142.53-
EBT Excluding Unusual Items
-97.7-70.92-33.65-6.17
Other Unusual Items
--7.39-1.12-
Pretax Income
-97.7-78.31-34.78-11.62
Income Tax Expense
--0.01-
Net Income
-97.7-78.31-34.79-11.62
Net Income to Common
-97.7-78.31-34.79-11.62
Shares Outstanding (Basic)
362121
Shares Outstanding (Diluted)
362121
Shares Change (YoY)
190.80%1277.25%93.74%-
EPS (Basic)
-2.72-3.78-23.10-14.95
EPS (Diluted)
-2.72-3.78-23.10-14.95
Free Cash Flow
-77.89-67.23-28.82-3.85
Free Cash Flow Per Share
-2.17-3.24-19.14-4.95
EBITDA
-109.1-82.22-36.07-5.84
D&A For EBITDA
1.010.840.110.02
EBIT
-110.11-83.06-36.18-5.85
Source: S&P Capital IQ. Standard template. Financial Sources.